9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

ConditionEpithelioid Mesothelioma|Pleural Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatoid MesotheliomaEstimated Enrollment: 116Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: TreatmentStudy ID Numbers: NCI-2011-02015|S0905|CDR0000665415|U10CA180888|U10CA032102Study First Received: February 5, 2010Last Updated: April 5, 2017Estimated Primary Completion Date: June 2017Primary Outcome Measures:Maximum tolerated dose determined if the dose-limiting toxicity rate is less than or equal to 33% according to NCI CTCAE version 4.0 (Phase I)|Progression-free survival (Phase II)|Overall survival (Phase II)|Response (Phase II)|Toxicity assessed using NCI CTCAE version 4.0 (Phase II)Sponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link:...

Continue reading

Nivolumab in Patients With Recurrent Malignant Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 33Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: N14MPNStudy First Received: July 6, 2015Last Updated: February 27, 2017Estimated Primary Completion Date: July 2017Primary Outcome Measures:DCR|PFS|OS|TTP|ORR|Safety and tolerability (The incidence of (serious) adverse events)Sponsors and Collaborators:The Netherlands Cancer Institute|Bristol-Myers SquibbResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02497508...

Continue reading

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

ConditionMesothelioma, MalignantEstimated Enrollment: 22Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: ONC-2014-002Study First Received: November 19, 2014Last Updated: February 9, 2017Estimated Primary Completion Date: December 2015Primary Outcome Measures:anti-tumor activity of Imatinib mesylate in combination with Gemcitabine|anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of Response Evaluation Criteria In Solid Tumors (RECIST) criteria|anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of overall survival (OS).|safety profile of the combination according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC)...

Continue reading

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

ConditionMesotheliomaEstimated Enrollment: 125Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: IFCT-1501Study First Received: March 9, 2016Last Updated: October 24, 2016Estimated Primary Completion Date: May 2017Primary Outcome Measures:Disease Control rate assessed by CT scan|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Progression-Free Survival|Overall Survival|Quality of Life|prognosis impact of blood biomarkers (exploratory studies)Sponsors and Collaborators:Intergroupe Francophone de Cancerologie ThoraciqueResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02716272...

Continue reading

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 390Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentStudy ID Numbers: NGR015|2009-016879-29Study First Received: March 17, 2010Last Updated: October 8, 2015Estimated Primary Completion Date: December 2016Primary Outcome Measures:Overall Survival (OS)|Progression-Free Survival (PFS)|Disease Control Rate (DCR)|Duration of Disease Control|Safety and Toxicity according to NCI-CTCAE criteria (version 4.02)|Quality of life (QoL) according to Lung Cancer Symptom Scale|Evaluation of medical care utilization in the two treatment armsSponsors and Collaborators:MolMed S.p.A.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01098266...

Continue reading

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

ConditionMalignant Pleural Mesothelioma|Non-Small Cell Lung CancerEstimated Enrollment: 24Age Group: 20 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: D8807005Study First Received: January 21, 2015Last Updated: July 19, 2016Estimated Primary Completion Date: May 2017Primary Outcome Measures:Phase1: Assessment of safety of BBI608 given in combination with Pemetrexed and Cisplatin by reporting the adverse events and serious adverse events.|Phase1: Assessment of dose-limiting toxicities (DLTs).|Phase1: Pharmacokinetics profile of BBI608 when administered with pemetrexed and cisplatin.|Phase2: Progression Free Survival (PFS)|Phase1: Anti-tumor activity|Phase1: Progression Free Survival(PFS)|Phase1: Overall Survival(OS)|Phase2: Overall Survival (OS)|Phase2: Response...

Continue reading

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

ConditionLung Cancer - Malignant Pleural MesotheliomaEstimated Enrollment: 27Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: UCL/12/0158|CMS # 1995|A15183|2012-001598-10|TBCStudy First Received: April 30, 2012Last Updated: October 26, 2016Estimated Primary Completion Date: September 2017Primary Outcome Measures:Maximum Tolerated Dose of Ganetespib|Progression Free SurvivalSponsors and Collaborators:University College, London|Cancer Research UKResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01590160...

Continue reading

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

ConditionLung Cancer|MesotheliomaEstimated Enrollment: 28Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 2014-0497|NCI-2014-02568Study First Received: November 11, 2014Last Updated: February 15, 2017Estimated Primary Completion Date: May 2021Primary Outcome Measures:Disease Control Rate (DCR)|Response RateSponsors and Collaborators:M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02293005...

Continue reading

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

ConditionMesothelioma|Adenocarcinoma of Lung|Pancreatic NeoplasmsEstimated Enrollment: 55Age Group: 18 Years to 99 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: TreatmentStudy ID Numbers: 110160|11-C-0160Study First Received: May 27, 2011Last Updated: April 20, 2017Estimated Primary Completion Date: August 3, 2016Primary Outcome Measures:Objective response rate stratified by tumor type|SS1P antibody formation|Grade and description of adverse events|determine RP2D in drug lot FIL129J01|Overall survival|Progression-free survival|Duration of responseSponsors and Collaborators:National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01362790...

Continue reading

Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 31Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: TreatmentStudy ID Numbers: 10-134Study First Received: December 21, 2010Last Updated: January 4, 2017Estimated Primary Completion Date: December 2017Primary Outcome Measures:To assess the 1-year progression free survival in patients|To confirm the immunogenicity of the WT-1 analog peptide vaccine|To assess the utility of using the serum marker|overall survivalSponsors and Collaborators:Memorial Sloan Kettering Cancer Center|United States Department of DefenseResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01265433...

Continue reading